Starting in February 2011, Springer will publish a new international, peer-reviewed journal Drug Delivery and Translational Research. Focusing exclusively on translational aspects of drug delivery, the bi-monthly journal will provide a unique forum for publication of high-quality research. It is an official journal of the Controlled Release Society (CRS).
Drug Delivery and Translational Research will publish research on such topics as designing and developing novel drug delivery systems, with a focus on their application to disease conditions; preclinical and clinical data related to drug delivery systems; short-term and long-term biocompatibility of drug delivery systems; nanomedicine, and other state-of-the-art technologies. In addition to original full-length papers, reviews, and editorial commentary, the journal will include brief communications, notice of future meetings announcements pertaining to activities of the Society. Dr. Vinod Labhasetwar of the Cleveland Clinic, Ohio, USA, is editor-in-chief. He is supported by an international editorial board with renowned experts from research centers and hospitals.
Drug Delivery and Translational Research will be published on Springer's online platform SpringerLink including Online First?, Cross Reference Linking, and Alert services. The journal will be provided to all members of the CRS as a benefit of membership.
Diane J. Burgess, President of the Controlled Release Society, said, "I am excited about this new CRS publishing initiative. With the tremendous growth in this area and incredible advances in nanomedicine that are just now starting to reach the clinics, this is precisely the right time to launch such a drug delivery and translational journal. Supported by our international network of top experts in this field, I anticipate that this new journal will hit the ground running."
Dr. William Curtis, Executive Vice President for Publishing at Springer, said, "Springer is delighted to be partnering with the Controlled Release Society to launch this exciting new publication. Our SpringerLink online platform will provide worldwide access to its high-value content. In doing so, the Society's publication will reach an ever growing multidisciplinary audience whose work focuses on enhancing drug delivery and optimizing the bioavailability of drug products for key disease states."